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Acute asthma or wheeze is a common presentation to emergency services for both adults
and children. Although there are phenotypic differences between asthma syndromes, the
management of acute symptoms follow similar lines. This article looks at the similarities
and differences in approaches for children and adults. Some of these may be age
dependent, such as the physiological parameters used to define the severity of the
attack or the use of age appropriate inhaler devices. Other differences may reflect the
availability of evidence. In other areas there is conflicting evidence between adult and
pediatric studies such as a temporary increase in dose of inhaled corticosteroids during
an acute attack. Overall there are more similarities than differences.
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INTRODUCTION
Asthma is the commonest chronic condition in the UK with a UK lifetime prevalence of
patient-reported clinician-diagnosed asthma of 15.6%. In 1 year asthma results in 6.3 million
primary care consultations and 93,000 hospital in-patient episodes. The costs of asthma are
estimated at £1.1 billion 12% of which is accounted for by hospital care and 14% for primary
care consultations (1). Many physicians in both adult and pediatric medicine across the whole
healthcare economy will therefore be expected to manage patients who may present with an acute
attack of their disease so knowledge of this area is very important for good patient care. Guidelines
for the management of an acute asthma attacks are documented in a number of national and
international publications (2–4). Management of an acute attack may start with treatment at home
and may progress to treatment in primary care, the emergency department and on the hospital
wards including intensive care. This article looks at similarities and differences in the management
of acute management between adults and children of varying ages.
The definition of asthma is difficult and there is no gold standard, and it is increasingly
recognized that asthma as a condition is made up of a number of phenotypes (5, 6). The
use of phenotypic variations is more likely to inform and modify chronic management, rather
than the acute management of a crisis at the present time. The first recognized presentation of
asthma is not uncommonly an acute attack, particularly in children, and therefore may present a
diagnostic challenge.
The British Thoracic Society and Scottish Intercollegiate Guidelines Network (BTS/SIGN)
asthma guideline precis the definitions of asthma as the presence of more than one symptom of
wheeze, breathlessness, chest tightness and cough associated with variable airflow obstruction.
Other definitions of asthma, in both children and adults, include airway hyper-responsiveness
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and airway inflammation as components of the disease
(BTS/SIGN) (2). The National Institute of Clinical Effectiveness
(NICE) have suggested a diagnosis should not be made without
objective evidence of airway obstruction or inflammation (3).
In younger children, particularly those <5 years of age,
the diagnosis of asthma (or phenotypes of wheeze) is difficult
and often controversial (7). Acute wheeze is however a very
common presenting complaint to both primary and secondary
care and may frequently be recurrent and troublesome. Whilst
the intricacies of diagnosis is beyond the context of this piece,
recognition of this difficulty is important. Asthma diagnosis
and phenotypes are subjects covered elsewhere in this series
of articles. As is not uncommon, the evidence for different
treatments are less well studied in the younger age groups. For
the purpose of this review it will be assumed that the diagnosis
of asthma is secure and we will be comparing / contrasting the
differences in children and adult asthma.
DEFINITION OF ADULTS AND CHILDREN
The definition of an adult will be taken as a person over 18 years,
accepting there is a considerable cross over in the adolescent
age group. In most hospital emergency departments, adolescents
under 18 are usually managed in the pediatric area, and if
necessary by pediatricians, although it is recognized that different
healthcare systems may have different policies. Guidelines and
clinical trials vary in their cut off ages with many studies
including adolescents over 12 in “adult” studies. Age cut offs
are clearly not as relevant to provision of care in primary care
and the home environment, however the age and maturity of
the individual patient should be considered when agreeing a
management plan. For children there are differences in the
approach to the young, preschool child (<5 years) and there is
very little evidence for the management of asthma symptoms in
children under 1 year of age.
DEFINITIONS & ASSESSMENT OF
ACUTE ASTHMA
An acute asthma attack represents a deterioration in
symptoms and lung function from the patient’s normal
status. Distinguishing between a lower respiratory tract infection
and an asthma attack can be challenging, particularly in young
children. This can include shortness of breath, wheezing, cough,
and chest tightness (4). Attacks are marked by a decrease from
baseline in objective measures of pulmonary function, such as
peak expiratory flow rate and FEV1. Objective measures, such
as FEV1 are less easy to perform in children and young persons,
and PEFR can be unreliable in children and young persons if they
have not used the technique before and are highly unlikely to be
achieved in children <5 years of age (8). In some individuals,
in particular those with poor adherence and/or more severe
asthma, there can be a challenge in distinguishing between a
mild asthma attack and long-standing poorly controlled asthma;
the challenge in in part due to symptoms being common to both
a mild asthma attack and poorly controlled asthma and in part
due to guidelines not defining criteria for a mild asthma attack.
Pharmacological management is entirely dependent upon the
severity of the attack which in turn is defined by a number of
objective and subjective findings. These differ between adults
and children, reflecting the age-related physiologic differences
and the reliability of pulmonary function testing in children.
Definitions from the BTS/SIGN and Global Initiative for Asthma
(GINA) guidelines are outlined in Table 1.
PRE-HOSPITAL MANAGEMENT OF
ACUTE ASTHMA
Adults are encouraged to have a personalized asthma action plan
(PAAP) in place which empowers them to increase treatments
in response to increasing symptoms or decreasing PEFR (9).
The PAAP should advise them when to seek medical assistance.
In children PAAPs advice only recommends increasing short
acting beta agonist. A Cochrane database systematic review of 4
clinical trials in children concluded that symptom-based PAAPs
are superior to peak flow PAAPs for preventing acute care
visits (10). There was insufficient data to firmly conclude how
symptom-based PAAPs were superior of the two. For example
the observed superiority of symptom-based PAAPs may have
been due to greater adherence to the monitoring strategy, earlier
identification of onset of deteriorations, higher threshold for
presentation to acute care settings, or the specific treatment
recommendations (10).
Most adult PAAPs recommend the increased use short acting
beta agonists at the onset of acute symptoms (11). Most pediatric
management plans suggest a titrated increased dose of beta-
2 agonist using doses between 2 and 10 puffs of a salbutamol
(pressure dose metered dose inhaler and spacer device) up to
every 4 h (12). Safety net advice to seek medical advice and
call an ambulance if not responding to treatment should be
included. Judicial use of rescue oral steroids at home is sometimes
included, although there is no consistent evidence of benefit for
this practice (13).
A second approach in adults may be the use of a single
combination inhaler for both preventer and relief [Maintenance
and Reliever Therapy: (MART)] which patients may titrate
in accordance to their symptoms (14). Preparations are not
currently licensed or in formulations for younger adolescents or
children in the UK.
A recent study in adults suggested a 4-fold increase in
inhaled steroid dose used early during an attack resulted in
fewer severe asthma exacerbations than a plan in which the
dose was not increased and this would be a reasonable self-
management strategy in this situation (15). A similar pediatric
paper suggesting a quintupled dose of ICS in children however
showed no benefit (16). This may reflect a difference in causation
of an attack, different responses by age or methodological
differences between the studies.
Any patients with features of acute severe or life-threatening
asthma should be referred to hospital immediately.
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TABLE 1 | Comparison of symptoms and signs associated with levels of acute asthma severity in adults and children the BTS/SIGN (1) and GINA (4) asthma guidelines.
BTS/SIGN GINA
Adult Children Adult & Children >5years Children (0-5)
Moderate Increasing symptoms
PEFR >50–75% best or predicted
No “severe” symptoms
Able to talk in sentences
SpO2 ≥ 92%
HR-≤140/min* or 125/min**
RR-≤40/min* or 30/min**
PEFR ≥50%** best or
predicted
No “severe” symptoms
Talks in phrases
Prefers sitting to lying
Not agitated
Respiratory rate increased
Accessory muscles not
used
Pulse rate 100-120 bpm
SaO2 in air 90-95%
PEF >50% predicted
or best
Breathless
Agitated
Pulse rate ≤200 bpm (0–3),
≤180 (4–5 years)
SaO2 ≥92%
Severe Any one of:
Inability to complete sentences in one breath
PEFR: 33–50% best or predicted
HR ≥ 110/min
RR ≥ 25/min
Can’t complete sentences
in one breath or too
breathless to talk or feed
SpO2 < 92%
HR ≥ 140/min* or
125/min**
RR ≥ 40/min* or 30/min**
PEFR 33–50%** best
or predicted
Talks in words
Sits hunched forwards
Agitated
Respiratory rate >30 bpm
Accessory muscles in use
Pulse rate >120 bpm
SaO2 <90% in air
PEFR ≤50% predicted
or best
Unable to speak or drink
Central cyanosis
Confusion or drowsiness
Marked subcostal and/or
sub-glottic retractions
SaO2 <92%
Silent chest on auscultation
Pulse rate >200 (0–3 years)
or >180 bpm (4–5 years)
Life threatening Severe attack with any of:
Altered conscious level
Exhaustion
Arrhythmia
Hypotension
Cyanosis
Silent Chest
Poor respiratory effort
PEFR <33% best or predicted
SpO2 <92%
PaO2 <8 kPa
Normal PaCO2 4.6–6 kPa
Severe attack with any
of:Silent Chest
Cyanosis
Poor respiratory effort
Hypotension
Confusion
Exhaustion
SpO2 <92%
PEFR <33%** best
or predicted
Drowsy
Confused
Silent chest
Near fatal Raised PaCO2 and/or requiring mechanical
ventilation
*children 1–5 years; **children over 5 years.
MEDICAL MANAGEMENT OF ACUTE
ASTHMA IN HEALTHCARE FACILITIES
Oxygen
It is essential to monitor oxygen saturations when assessing an
asthma attack. In adults there is evidence that hyperoxia may be
detrimental plus there is also a possibility that the patient may
have chronic obstruction so that the delivery of oxygen should be
controlled to maintain an SpO2 level of 94–98% (17).
In children with saturations <92% in air after initial
bronchodilator treatment it is advised that inpatient hospital
treatment will be required as this reflects more severe asthma
(18, 19). Oxygen should be administered to any child with acute
asthma with SpO2 <94% via a tight fitting face mask or nasal
cannula at sufficient flow rates to achieve normal saturations
of 94–98%.
Short Acting Bronchodilators
The initial management of an acute asthma attack is usually
given by the inhaled route. In adults it is recommended that in
non-life threatening acute asthma, beta agonists can be given
through repeated actuations of a pMDI via an appropriate large
volume spacer. The recommendation is to give 4 puffs (400
mcg) as the initial dose and increase by 2 puffs every 2min up
to 10 puffs if needed. In life threatening asthma however wet
nebulization of beta agonists with oxygen is preferable. Adult
patients who do not respond to initial nebulization of beta agonist
may be considered for repeated doses at 15–30min intervals or
continuous nebulization at 5–10 mg/h (2).
In Children, a pMDI and age-appropriate spacer device is the
preferred option for delivering inhaled beta agonists with mild to
moderate asthma as this is less likely to produce a tachycardia and
hypoxia than using a nebulizer (20, 21). A facemask connected
to the mouthpiece of a spacer is recommended in children <3
years old. In children drug dosing should be escalated as required
from two puffs of salbutamol suitable for mild attacks up to 10
puffs for more severe attacks with 30–60 s between puffs. The
inhalers should be activated into the spacer in in individual puffs
and inhaled immediately by tidal breathing (for five breaths).
In the hospital setting, with appropriate monitoring, doses can
be repeated every 20min over an hour if necessary. In children
with severe or life-threatening asthma should receive nebulized
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bronchodilators driven by oxygen. These can be given in
combination with ipratropium bromide which is recommended
if there is a poor response to salbutamol alone (22). Repeated
doses can be given every 20min over a 1–2 h period. In contrast to
adult recommendations continuous nebulized beta agonists are
of no greater benefit than the use of frequent intermittent doses
in the same hourly dosage (2, 23, 24).
After the first few hours salbutamol can be tapered down to
one to two hourly and ipratropium tapered to four to six hourly
or discontinued. In adults ipratropium bromide is recommended
in acute severe or life-threatening asthma but is not necessary in
milder asthma attacks or after stabilization.
Steroids
For adults and children it is important to give steroids early
during an acute attack. Steroid tablets are as effective as injected
steroids and should be given for at least 5 days in adults or until
recovery. Evidence for the ideal duration of oral steroid treatment
is still required (25). Once recovery is achieved, steroids can be
stopped abruptly and do not need to be tapered unless the patient
is on maintenance steroids or if they have received a prolonged
course of three or more weeks (26). Inhaled steroid treatment
should continue during prescription of oral steroids (2).
In children, oral prednisolone is the steroid of choice
for asthma attacks and intravenous corticosteroids are only
indicated for children who are vomiting or who have very
severe symptoms which prevent swallowing (27). Some studies
using dexamethasone have shown potential equivalence to
prednisolone with the potential to reduce the number of doses
and therefore potentially improving treatment adherence (28).
The use of oral steroids is more controversial in preschool
children (age 1–5). This may reflect the presence of common
symptoms in asthma and lower respiratory tract infection in
this age group. Additionally there may be more than one acute
asthma phenotype, but one study considered this and found
no difference in outcome between children with “viral induced
wheeze” with and without atopy (29). Different prednisolone
dose schedules have been recommended from 0.5–2mg /kg (30)
and others recommend an age related dose schedule (2). In
children recommendations are usually for 3 days of treatment
but may need to be extended from 5 to 10 days to bring about
recovery. Tapering is not necessary unless the course exceeds
14 days.
There is no evidence to support the use of Inhaled steroids
as an alternative to oral steroids during an asthma attack of this
severity but it is good practice to continue the usual maintenance
inhaled steroids during an attack (2).
Second Line Treatments
Magnesium
There is some evidence that intravenous magnesium sulfate has
bronchodilator effect during an acute asthma attack (31). In
adults there is limited evidence that a single dose of iv magnesium
may be some benefit in adults with a PEF <50%. This is felt to be
safe and may improve lung function and reduce intubation rates
in those with acute severe asthma. It may also reduce admission
to hospital with asthma from ED in adults who have had little
or no response to standard treatment. It should only be used
following consultation with senior medical staff (2).
The use of IV magnesium has become more frequent in
children with acute asthma. There is relatively little evidence
compared to other intravenous therapies although there is
one comparative study showing a more rapid improvement
compared to IV salbutamol or aminophylline (32). It is generally
safe with few side effects. It should be used if there is a poor
response to first line therapies and is not recommended in mild
to moderate asthma attacks.
The use of nebulized magnesium has been studied in one large
UK based trial (33). Overall the benefits were small although did
seem to offer some benefit when added to nebulized salbutamol
and ipratropium in the first hour of hospital treatment in
children presenting with a short duration of acute severe asthma
symptoms presenting with an SpO2 <92% (34). At the time of
writing, the role of nebulized magnesium in both adults and
children is uncertain.
Aminophylline
In adults evidence suggests that the addition of intravenous
aminophylline is unlikely to add any additional bronchodilation
compared to standard care and side effects such as arrhythmias
and vomiting are increased (35). However, patients with near
fatal asthma with a poor response to initial therapy may gain
additional benefit from IV aminophylline. It is advised that before
its use consultation should take place with a senior member of
medical staff as these patients are likely to be rare (2).
In children, aminophylline was previously considered the
first line IV treatment following a poor response to initial
management (bronchodilators and steroids) but now intravenous
magnesium is recommended as first line due to reduced side
effects and equal efficacy (2). There is some evidence of benefit
in severe or life threatening asthma (36). The risk of side effects
is high and ECG monitoring is recommended with the patient
monitored in an HDU/PICU environment.
IV Salbutamol
There may be some benefit for the use of IV salbutamol in
both adults and children who have not responded to first line
treatments and IV magnesium (37).
In children an initial bolus dose (15 mcg/kg) may be given.
In comparison with IV aminophylline (bolus and infusion)
this has been shown to give equivalent results. Initially it was
thought to cause fewer side effects compared to aminophylline
but more recently nausea, tachycardia and lactic acidosis have
been frequently recognized. There is very limited evidence for the
use of a salbutamol infusion in children but is sometimes utilized
in the PICU environment.
Antibiotics
In adults an infection precipitating an attack is most likely
to be viral and therefore routine prescription of antibiotics is
not indicated. Objective measures such as serum procalcitonin
where available should be used to guide decisions on using
antibiotics (2).
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TABLE 2 | Summary of similarities and differences in the diagnoses, assessment
and treatment of acute asthma in adults and children.
Similarities Differences
Diagnosis Same symptoms Challenge in distinguishing
from lower respiratory tract
infection may be greater in
children
Assessment The same physiological
parameters are used in
assessment (i.e.,
Respiratory rate, Heart rate,
Oxygen saturations)
Physiological parameters
differ numerically between
adults and children.
Achievability and reliability of
PEFR and FEV1 in children
is lower than in adults
Stepping up
treatment
Actions plans recommend
using short acting beta
agonists when symptoms
occur
Only adult personal action
plans (based on good
evidence) recommend
MART of quadroupling ICS
dose for worsening
control/minor asthma
attacks
Supplemental
oxygen
treatment
Required when oxygen
saturation are below 92% in
all age groups
Aim for ceiling 98% in adults
due to potential overlap with
COPD
First line
treatment
Same medications used Doses differ in children and
adults, e.g., initial short
acting beta agonist 400
microg in adults but in
children is 200 microg
increasing to 1,000 microg
Second line
treatment
Same medications used
(i.e., intravenous
magnesium, salbutamol and
aminophylline)
No major differences at this
level
In children the role of bacterial infection is also less
common than a viral trigger. Antibiotics are not recommended.
Procalcitonin is not routinely used at present in children. CRP is
more frequently used but less specific.
Critical Care
In both adults and children with acute asthma and a poor
response to standard therapy it is important to involve clinicians
with the appropriate skills in airway management and critical
care support early. There is little good quality evidence to guide
treatment at this stage and a national audit of treatment for acute
asthma in adults in the UK found a wide variation in clinical
practice (38).
In adults admission to critical care is recommended in those
requiring ventilator support and acute severe life-threatening
asthma indicated by: deteriorating PEF, persisting or worsening
hypoxia, hypercapnia, arterial blood gas analysis showing fall
in pH or rising hydrogen concentration, exhaustion, feeble
respiration, drowsiness, confusion, altered conscious state or
respiratory arrest (2).
In children admitted to hospital with status asthmaticus two
small studies have reported the use of non-invasive ventilation
suggesting that it is safe and feasible but there was insufficient
evidence of its effectiveness. In adults there has also been
suggestions that the use of NIV can be safe and effective however
the evidence is limited and inconclusive. One trial of NIV in a
small number of patients showed improvement in hospitalization
rates, discharge from emergency departments and lung function.
Other trials have shown safety and feasibility of using NIV in
treating acute exacerbations of asthma but little evidence of
benefit in comparison with standard care. It is recommended
that NIV should only be considered in adults in a critical care
or equivalent setting (2).
Invasive ventilation strategies are beyond the scope of
this article.
The BTS asthma guidelines are able to recommend the
following advice for therapies at this stage. In both adults
and children Ketamine may be considered as a potential
bronchodilator although further prospective trials are required
before conclusions about effectiveness can be drawn (39, 40).
In children the anesthetic gas Sevoflurane is potentially an
option for correcting high levels of PaCO2 in mechanically
ventilated children however its use would be limited to areas
where appropriate scavenging facilities to extract gas are
available (41).
There is an increasing trend in the use of Recombinant DNase
in pediatric intensive care in children with acute asthma due
to airway plugging. There is little or no published evidence to
support this practice. A study in non-intubated adults with severe
asthma showed no improvement in FEV1 (42).
Extracorporeal Membrane
Oxygenation (ECMO)
ECMO is a form of cardiopulmonary life-support, where blood
is drained from the vascular system, circulated outside the body
by a mechanical pump, and then reinfused into the circulation.
While outside the body, hemoglobin becomes fully saturated with
oxygen and CO2 is removed. Oxygenation is determined by flow
rate, and CO2 elimination can be controlled by adjusting the
rate of countercurrent gas flow through the oxygenator. It is
a highly specialized form of treatment and available in only a
few centers in the UK. It has been shown to be useful and an
option in severe asthma refractory to mechanical ventilation in
both children and adults by providing adequate gas exchange and
preventing lung injury. However, careful management is required
to avoid complications (43).
Discharge and Follow Up
In adults it is recommended discharge can be considered when
clinical signs are compatible with homemanagement i.e., medical
therapy can continue safely at home. Patients with PEF <75%
best or predicted and diurnal variability of PEF >25% are at
greater risk of early relapse and readmission therefore this should
be borne in mind when deciding on timing of discharge. This is
also true in children (2).
In both adults and children it is important to assess and attend
to correct risk factors that may have lead to a loss of control of
asthma leading to admission e.g., smoking or exposure to smoke
in the household in children. Education prior to discharge is
important including advice on inhaler technique, a review of the
personal asthma plan and, if used, PEF record keeping. Tools
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such as the BTS asthma discharge bundle are available to provide
help with this process (44).
All patients both adult and children should have an
appointment arranged with their primary care team within 48 h
of hospital discharge. Secondary care review should be arranged
within a few weeks.
CONCLUSION/SUMMARY
There are similarities and differences in the diagnoses, assessment
and treatment of acute asthma in adults and children, and
these are summarized in Table 2. The mainstay of management
is to ensure early assessment of severity with appropriate
use of bronchodilators with corticosteroids. There are some
differences in the recommendations of how these medications
are given and their associated doses but because the pathological
processes are essentially the same the general principles of
treatment are also the same. The more cautious use of
oral corticosteroids in children may reflect concern over
longer term side effects as well as questionable response
in preschool children. The use of variable dose regimes of
inhaled steroids may reflect the availability of suitable drug
preparations and the difference between an individual feeling
their own innate symptoms and a parent recognizing their
child’s symptoms.
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